- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07607015
CGM Experience, Preferences & Blood Glucose Parameters
Instara™-1 Dual Perspectives on Continuous Glucose Monitoring: Understanding Patient Experience and Healthcare Professional Preferences
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
This study aims to assess the real-world experience and perceived benefits of the Instara-1 Continuous Glucose Monitoring system among patients and healthcare professionals.
Patients diagnosed with diabetes will be enrolled after providing written informed consent. Instara-1 sensor placement will be performed at baseline, screening, and patients will be followed at Week 3, Week 6, Week 9, and Week 12 after CGM initiation. Patient assessments will include user experience, perceived benefits, preference, CGM-derived glucose parameters including estimated HbA1c and Time in Range, laboratory parameters including HbA1c, and diabetes-related quality of life using DQoL-13.
Healthcare professionals will participate to assess device-related experience, usability, preference, and comparison of Instara -1 with FreeStyle Libre 2. HCPs will complete the relevant user experience assessment at baseline before sensor insertion and at Week 3 after device use.
The primary outcomes will focus on perceived benefits, device experience, and preference related to CGM use among patients and HCPs. Secondary outcomes will assess changes in glucose-related parameters and diabetes-related quality of life among patients from baseline to the end of the study.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Jahanzeb Kamal Khan, MCPS
- Telefonnummer: +923201212945
- E-mail: jahanzeb.kamal@getzpharma.com
Undersøgelse Kontakt Backup
- Navn: Nauman Muhammad Sheikh, MBBS
- Telefonnummer: +923201212981
- E-mail: nauman.shaikh@getzpharma.com
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Subjects to provide written informed consent prior to any study procedures being performed
- Subjects with age 18 and above both male and female
- Diagnosed with Diabetes Miletus Type I, Type II and/or GDM
- Comfortable using smart phone, access to internet along with Bluetooth connectivity throughout the study duration.
- Subjects (Patients) on oral or injectable anti-diabetic medications, (in case of insulin, patient must be on insulin from last 3 months )
- Subjects (HCPs) healthy, Pre-diabetes or Diabetes Miletus (any type)
Exclusion Criteria:
- History of hypersensitivity to any of the active or inactive ingredients of the CGM device used in the trial, and/or history of significant allergic skin reactions.
- Presence of severe diabetes complications e.g. retinopathy, acute metabolic crisis, etc.
- History of active/ acute renal and/or hepatic failure.
- Patients who have been admitted to the hospital in the past 3 months for diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state.
- History of critical illness or incapacitated patients
- History of acute psychiatric disorder or exacerbation of chronic psychiatric disorder.
- History or presence of a medical condition or disease that in the investigator's opinion would embarrass glycemic control and completion of the study.
- Medical conditions that require patients to undergo frequent radiation/ imaging procedures for example CT, MRI and X rays
- History of known hematological disorders such as Sickle Cell Disease & Trait, Thalassemia, Hemolytic Anemias (e.g., G6PD deficiency, autoimmune), Iron Deficiency Anemia
- Patients on high doses of acetaminophen (>1 gram every 6 hours), ascorbic acid supplements (e.g., > 500-1000 mg/day), IV sorbitol, steroids and aspirin which can alter the readings on the CGM device.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Instara-1 CGM
Participants in this arm will use the Instara-1 Continuous Glucose Monitoring .
Patients will be followed for device experience, perceived benefits, preference, glucose-related parameters, and diabetes-related quality of life.
Healthcare professionals will assess device experience and preference, including comparison with FreeStyle Libre 2 where applicable.
|
Comparison of 2 devices by HCP
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Benefit, device experience and preference of continuous glucose monitoring by patients and HCPs
Tidsramme: From enrollment to the end of treatment at 3 weeks.
|
A user experience questionnaire will be used to assesses how glucose monitoring helps in overall diabetes management, including understanding the effect of food, exercise, and stress on glucose levels, recognizing glucose trends, improving self-management and decision-making, increasing confidence and safety, supporting better communication with healthcare providers improving overall quality of life with diabetes.
A 5 point Likert scale will be used to translate subjective experience into structured, comparable feedback
|
From enrollment to the end of treatment at 3 weeks.
|
|
Sensor and mobile application experience of continuous glucose monitoring by patient and comparison with Free Style®Libre 2
Tidsramme: From the time of enrollment to end of week 3.
|
The study will use an evaluation Questionnaire focusing on the usability of the sensor and mobile app.
To capture functional experience, behavioral and emotional impact a 5 point Likert scale will be used to translate subjective experience into structured, comparable feedback with 1 being strongly disagree and 5 being strongly agree.
The questionnaire will include questions regarding, comfort of wearing the sensor, interference with daily life, pain or inconvenience, perceived reliability of glucose readings, system performance throughout use, overall user friendliness and willingness to use sensor again or recommend it to others.
|
From the time of enrollment to end of week 3.
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
eHbA1c%
Tidsramme: At week1, week 3, week 6, week 9 and week 12
|
At week1, week 3, week 6, week 9 and week 12
|
|
Time in range (TIR), time above range (TAR) and time below range (TBR) .
Tidsramme: Week 1, week 3 , week 6, week 9 and week 12
|
Week 1, week 3 , week 6, week 9 and week 12
|
|
Mean difference in HbA1c% from laboratory
Tidsramme: Baseline and at week 12
|
Baseline and at week 12
|
|
Mean difference in Quality of Life (DQoL 13)
Tidsramme: At baseline, week 6 and week 12
|
At baseline, week 6 and week 12
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studieleder: Jahanzeb Kamal Khan, MCPS, CPSP
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Sygdomme i det endokrine system
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Metaboliske sygdomme
- Graviditetskomplikationer
- Glukosemetabolismeforstyrrelser
- Hyperglykæmi
- Ernæringsmæssige og metaboliske sygdomme
- Diabetes, svangerskabssyge
- Diabetes mellitus
- Glucoseintolerance
Andre undersøgelses-id-numre
- GTZ-CGM-018-05-26
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diabetes mellitus
-
State University of New York at BuffaloMedical University of South CarolinaAfsluttetDiabetes mellitus | Type 2 diabetes mellitus | Voksen-debuterende diabetes mellitus | Ikke-insulinafhængig diabetes mellitus | Ikke-insulinafhængig diabetes mellitus, type IIForenede Stater
-
Meir Medical CenterAfsluttetDiabetes mellitus type 2 | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, om oral hypoglykæmisk behandling | Voksen type diabetes mellitusIsrael
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AfsluttetDiabetes mellitus, type 1 | Type 1 diabetes | Diabetes type 1 | Type 1 diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinafhængig | Juvenil-Debut Diabetes | Diabetes, autoimmun | Insulinafhængig diabetes mellitus 1 | Diabetes mellitus, insulinafhængig, 1 | Diabetes mellitus, skør | Diabetes Mellitus... og andre forholdForenede Stater
-
SanofiAfsluttetType 1-diabetes mellitus-type 2-diabetes mellitusUngarn, Den Russiske Føderation, Tyskland, Polen, Japan, Forenede Stater, Finland
-
Medtronic MiniMed, Inc.RekrutteringType 2 diabetes mellitus | Type 1 diabetes mellitusForenede Stater, Australien, New Zealand
-
Peking Union Medical College HospitalUkendtType 2 diabetes mellitus | Type 1 diabetes mellitus | Svangerskabsdiabetes mellitus | Pancreatogen diabetes mellitus | Prægestationsdiabetes mellitus | Diabetespatienter i perioperativ periodeKina
-
Insulet CorporationRekrutteringType 2 diabetes mellitus | Type 1 diabetes mellitusForenede Stater
-
State University of New York at BuffaloMedical University of South Carolina; National Institute of Diabetes and...AfsluttetDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
-
State University of New York at BuffaloNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
-
Guang NingRekrutteringType 2 diabetes mellitus | Type 1 diabetes mellitus | Monogenetisk diabetes | Pancreatogen diabetes | Lægemiddel-induceret diabetes mellitus | Andre former for diabetes mellitusKina
Kliniske forsøg med CGM
-
University of Ljubljana, Faculty of MedicineAfsluttetType 1 diabetes mellitusSlovenien
-
Jaeb Center for Health ResearchDexCom, Inc.Afsluttet
-
University Hospital PadovaBoston Children's Hospital; University of PadovaAfsluttetSpædbarn, meget lav fødselsvægt | Neonatal hypoglykæmiForenede Stater, Italien
-
University of MinnesotaRekruttering
-
Shanghai 6th People's HospitalShenzhen Center for Chronic Disease Control; Shenzhen Baoan District People... og andre samarbejdspartnereRekruttering
-
Jaeb Center for Health ResearchThe Leona M. and Harry B. Helmsley Charitable Trust; Indiana University...AfsluttetType 1 diabetes mellitusForenede Stater
-
DexCom, Inc.Jaeb Center for Health ResearchAfsluttetDiabetes mellitusForenede Stater, Canada
-
Intermountain Health Care, Inc.AbbottAktiv, ikke rekrutterendeDiabetes mellitus, type 2Forenede Stater
-
DexCom, Inc.AfsluttetDiabetes mellitusForenede Stater
-
Joslin Diabetes CenterDexCom, Inc.AfsluttetHypoglykæmi | Hypoglykæmi, ReaktivForenede Stater